Barbara E Bierer

Barbara Emily Bierer, MD

Professor of Medicine (Pediatrics), HMS
Member, HMS Center for Bioethics

Barbara Bierer, MD is a Professor of Medicine (Pediatrics) at Harvard Medical School (HMS), and a hematologist/oncologist at the Brigham and Women's Hospital (BWH). She received her MD from HMS. She is the director of the Regulatory Foundations, Law and Ethics Program of the Harvard Catalyst, the Harvard Clinical and Translational Science Award, and the director of regulatory policy, SMART IRB. Dr. Bierer co-founded and now leads the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center), a University-wide and collaborative effort to improve the ethics, conduct, and regulatory environment for multi-site, multi-national clinical trials. She is a co-founder of COVID-19 Collaboration Platform, a platform for cooperation in research. In 2017, the MRCT Center launched the non-profit Vivli, a global clinical research data sharing platform. From 2003-2014, she served as Senior Vice President, Research, at BWH and was the institutional official for human subjects and animal research, for biosafety and for research integrity at the BWH. She initiated the Brigham Research Institute and the Innovation Hub (iHub), a focus for entrepreneurship and innovation. Dr. Bierer established and directed the Center for Faculty Development and Diversity at the BWH; for these efforts, she was the first recipient of the HMS Harold Amos Faculty Diversity Award.

Publications View
Cross-linking CD28 leads to activation of 70-kDa S6 kinase.
Authors: Authors: Pai SY, Calvo V, Wood M, Bierer BE.
Eur J Immunol
View full abstract on Pubmed
CD59 costimulation of T cell activation. CD58 dependence and requirement for glycosylation.
Authors: Authors: Menu E, Tsai BC, Bothwell AL, Sims PJ, Bierer BE.
J Immunol
View full abstract on Pubmed
Molecular and biological actions of cyclosporin A and FK506 on T cell development and function.
Authors: Authors: Holländer GA, Bierer BE, Burakoff SJ.
Transfus Sci
View full abstract on Pubmed
Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease.
Authors: Authors: Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, Parsons SK, Ballen KK, Rimm IJ, Falzarano G, et al.
Blood
View full abstract on Pubmed
Adhesion receptors in lymphocyte activation.
Authors: Authors: Collins TL, Kassner PD, Bierer BE, Burakoff SJ.
Curr Opin Immunol
View full abstract on Pubmed
Activation-dependent phosphorylation of the T-lymphocyte surface receptor CD28 and associated proteins.
Authors: Authors: Hutchcroft JE, Bierer BE.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Immunophilins in protein folding and immunosuppression.
Authors: Authors: Fruman DA, Burakoff SJ, Bierer BE.
FASEB J
View full abstract on Pubmed
Cyclosporin A, FK506, and rapamycin: binding to immunophilins and biological action.
Authors: Authors: Bierer BE.
Chem Immunol
View full abstract on Pubmed
Biology of cyclosporin A and FK506.
Authors: Authors: Bierer BE.
Prog Clin Biol Res
View full abstract on Pubmed
Structural organization of the genes encoding human and murine FK506-binding protein (FKBP) 13 and comparison to FKBP1.
Authors: Authors: Hendrickson BA, Zhang W, Craig RJ, Jin YJ, Bierer BE, Burakoff S, DiLella AG.
Gene
View full abstract on Pubmed